Board committee backs draft amendments to align outsourcing-facility rules with federal definitions

The Enforcement & Compounding Committee of the California State Board of Pharmacy reviewed proposed statutory language on Jan. 7 that would update state law to mirror federal definitions for outsourcing facilities and reduce points of regulatory mismatch.

Chair Maria Serpa opened the discussion by noting the proposed omnibus amendments would target a set of Business and Professions Code sections and align state language with the Food and Drug Administration’s definitions in Title 21. "Outsourcing facilities are also permitted to compound nonsterile drugs," Serpa said during the presentation, and staff emphasized that drugs made by outsourcing facilities remain subject to current good manufacturing practice requirements under the FD&C Act.

Staff outlined several edits in Attachment 2 to the meeting materials: adding the phrase "geographic location or address" to the definition of an outsourcing facility; striking "non-patient specific" from a BPC provision to reflect AB1533’s change allowing some patient-specific compounding; and replacing the word "licensed" with "registered" in cross-references to the FDA, because outsourcing firms hold FDA registrations rather than licenses.

Committee members expressed general support. Licensing member Renee Barker called the package "small but mighty changes" that would clarify alignment for 503(b) facilities. There was no public comment on the proposed statutory language during the committee discussion.

The committee signaled that it would refer the draft language to the full board for review and possible action. Staff noted the referral would allow the full board to consider the suggested edits and any additional counsel-recommended refinements before any legislative or regulatory steps.